Webinars
Challenges and role of serology in the next phase of COVID-19 responses
Learn about COVID-19 and the importance of serology investigation in viral disease outbreak.
Citations
- Toelzer, C. et al . Unexpected free fatty acid binding pocket in the cryo-EM structure of SARS-CoV-2 spike protein. bioRxiv doi: 10.1101/2020.06.18.158584(2020).
- Tan C.W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat. Biotechnol. (2020).
- Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature https://doi.org/10.1038/s41586-020-2550-z. (2020).
- Bond K. et al. Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. The Journal of Infectious Diseases. (2020).
- Peiris M. et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera. medRxiv doi:10.1101/2020.07.28.20163592. (2020).
- Addetia A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. medRxiv doi:10.1101/2020.08.13.20173161. (2020).
- McGregor R, et al. Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand. PeerJ 8:e9863 DOI 10.7717/peerj.9863. (2020).
- Chen W, et al. SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia. Biomedicine & Pharmacotherapy, volume 130, 2020, 110629.
FAQs
- The test uses the interaction between viral protein-receptor protein to mimic the virus infection of a live cell, which is monitored by a chromogenic reaction.
- When there are neutralizing antibodies in the patient sera, they will block the specific protein-protein interaction and hence reducing the chromogenic reaction, mimicking the virus neutralization process.
- Allows rapid detection of neutralizing antibodies without the need of live virus and biosafety containment.
- Suitable for all antibody isotypes.
- Can be used across different species, such as human, animal or other biological samples without any adjustment of the protocol.
- Most COVID-19 antibody test kits in the market evaluate the ability of a patient to generate antibodies bind virus, such as IgG, IgM, or total antibody, but they do not tell whether such antibodies can neutralize the virus and break virus life cycle, which is essential for a person’s acquired immunity against the pathogen. Our kit detects the antibodies that have blocking/neutralization function. Therefore, it is a better measure of potential resilience to re-infection.
- Traditionally, the presence of neutralizing antibodies are detected by virus neutralization test(VNT). Conventional virus neutralization tests require live viruses and cells, biosafety containment facilities, highly skilled operators, are less sensitive, and take days to obtain results. Our cPass™ test does not involve live virus and cells and can be used in any lab, except the test sample itself is infectious and need biosafety level 2 or 3 (BSL2, BSL3) labs. The operation steps are much more straightforward and only take 1 hr to run.
- The standard virus neutralization test (VNT) uses live virus to infect human cells. Anything that can inhibit the infection can be recognized as a neutralization agent. This method has been the gold standard. However, the process is tedious (takes days) and requires using high level safety lab facility (biosafety level 3). Therefore, the assay is expensive and cannot be widely used.
- Another approach is pseudovirus neutralization test, it is specific and can be performed in BSL2 labs. However, it is still dependent on live cells and virus and is hard to commercialize.
- Our kit measures protein-protein interaction which does not require live cells or virus. Our kit can be used in any laboratories unless you are handling health hazardous samples, which requires BSL2 or BSL3 based on local regulation. It can also amenable to automation.
- When using as serology test on patients, if the cPass™ test gives a positive result, it means the person most likely has been infected by the virus in the past, indicating potential immunity against the virus. With this serology test, large amount of data can be provided for epidemiologic study.
- In the society or community, this is the most practical way to evaluate the level of “herd immunity”.
- It can be used to test whether an animal or a pet has been infected by COVID-19 virus. In zoology studies, this can be used to find out the animal intermediate host of COVID-19.
- In vaccine development, it can be used to evaluate the ability of vaccines to generate such antibodies in vaccine immunized population, and to measure how long the neutralizing antibodies exist.
- In clinical therapeutics, this kit can be used to identify which donor has the functional neutralization antibodies, and with confirmed negative qRT-PCR that shows viral clearance, the individuals might be a qualified volunteer to donate serum for passive therapeutics to save seriously ill patients.
- This kit can also be used to screen therapeutic antibodies, which are engineered to block the interaction between RBD and ACE2.
- As our kit is species-independent, customers can use our kit to screen antibodies derived from any host, such as mouse, rabbit, human, or llama.
- cPass™ can also be used by researchers to identify the intermediate host between bat and human, which is a critical missing link when we try to trace the origin of the pandemic.
- cPass™ is useful to screen animals in contact with human, which helps to build guidelines on which animal may contract SARS-CoV-2 and how should such risk be mitigated.
- The cPass™ kit is a serology test that checks the neutralizing antibody against SARS-Cov-2 in response to infection. It should not be used to diagnose acute SARS-CoV-2 infection, as the antibodies could not be generated in a short time period.
- On the other hand, an individual with past infection but already have virus clearance may still have neutralizing antibody as acquired immunity.
- Diagnostic tests are molecular tests that mainly check genetic material from the virus itself, usually by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR), to diagnose active infections through nasal swab, throat swab, saliva, etc.
- No, our test requires a simple ELISA plate reader that is typically available in almost all clinical diagnostics labs. We are adapting it to run on some popular automated ELISA systems.
- The test takes about 1hr after collecting the samples.
- Prior to run the test, human or animal specimen may takes 40min to prepare.
- Yes, since it is an ELISA test, it can adapt to automation easily. We have customers use the test in an automated liquid handler.
Distributors
Asia Pacific
- Company: Dow Biomedica Inc.
- Address: F6 Dow Building 29 Yangsan-ro Songpa-ku, Seoul, Korea
- Tel: +82 2 2201 2602
- Fax: +82 22201 2166
- Email: [email protected]
South Korea
- Company: Tembusu Healthcare Pte Ltd
- Address: 1 Scotts Road #24-10 Shaw Centre Singapore 228208
- Tel: +65 9662 2977
- Email: [email protected]
- Web: https://www.tembusuhealthcare.com/
Philippines
- Company: Premas Life Sciences Pvt Ltd
- Address: E-49/5, IInd Floor, Okhla Phase-2 New Delhi - 110020
- Tel: +91 11 46170798
- Email: [email protected]
- Web: https://premaslifesciences.com/
India
Europe
- Company: tebu-bio NV
- Address: Alexander Franckstraat 196
- B-2530 Boechout
- Tel: 03/ 454 00 66
- Fax: 03/ 454 18 88
- Email: [email protected]
- Web: https://www.tebu-bio.com/
Belgium
- Company: Biospectra d.o.o.
- Address: Industrijska cesta 5B.
- 5000 Nova Gorica
- SLOVENIJA
- Tel: +386 (0)5 333 13 28
- Fax: +386 (0)5 302 5335
- Email: [email protected]
Croatia
- Company: tebu-bio
- Address: CAT Science Park
- Universitetsparken 7
- 4000 Roskilde - Denmark
- Tel: +45 46 74 02 54
- Email: [email protected]
- Web: https://www.tebu-bio.com/
Denmark
- Company: tebu-bio
- Address: CAT Science Park
- Universitetsparken 7
- 4000 Roskilde - Denmark
- Tel: +45 46 74 02 54
- Email: [email protected]
- Web: https://www.tebu-bio.com/
Finland
- Company: CliniSciences
- Address: 74, rue des Suisses
- 92000 Nanterre - France
- Tel: +33 9 77 40 09 09 / +33 1 42 53 14 53
- Fax: +33 9 77 40 10 11 / +33 1 46 56 97 33
- Email: [email protected]
- Company: tebu-bio SAS
- Address: 39 rue de Houdan - BP 15
- 78612 Le Perray-en-Yvelines Cedex
- Tel: 01 30 46 39 00
- Fax: 01 30 46 39 11
- Email: [email protected]
- Web: https://www.tebu-bio.com/
France
- Company: LaboSpace SRL
- Address: Via Apelle, 41
- 20128 Milano
- Tel: +39 02 359 80841
- tebu-bio Srl
- PI/CF 12410660158
- Via Pretorio 4 - C.P. 70
- I-20013 Magenta (MI)
- Tel: 02 97 29 50 10
- Fax: 02 97 29 50 77
- Email: [email protected]
- Web: https://www.tebu-bio.com/
Italy
- Company: Bio-Science Kft.
- Address: 1119 Budapest, Fehérvári út 79.
- Tel: 06-1-619-8321 / 06-1-619-8316
- Fax: 06-1-799-0159
- Mobile: 06-30-620-5356; 06-30-987-1992; 06-30-740-5864
- Email: [email protected]
- Web: https://www.bio-science.hu/kapcsolat
Hungary
- Company: tebu-bio BV
- Address: Stationsplein 99 Unit 167
- 1703 WE Heerhugowaard
- Tel: 072-572 21 00
- Email: [email protected]
- Web: https://www.tebu-bio.com/
Luxembourg
- Company: tebu-bio BV
- Address: Stationsplein 99 Unit 167
- 1703 WE Heerhugowaard
- Tel: 072-572 21 00
- Email: [email protected]
- Web: https://www.tebu-bio.com/
The Netherlands
- Company: tebu-bio
- Address: CAT Science Park
- Universitetsparken 7
- 4000 Roskilde - Denmark
- Tel: +45 46 74 02 54
- Email: [email protected]
- Web: https://www.tebu-bio.com/
Norway
- Company: LabNet Biotechnica
- Address: Calle Maldonado, 56 - 28006 - Madrid – España
- Email: [email protected]
- Web: https://www.labnet.es/
- Company: tebu-bio Lda
- Address: Av. António Serpa, n°32, 4C
- 1050-027 Lisboa
- Tel: +351 215 842 958
- Email: [email protected]
- Web: https://www.tebu-bio.com/
- Company: VITRO S.A.
- Address: Av. Almirante Reis, N 114, 3 C - 1150-023 Lisboa
- Tel: +351 961 342 712
- Email: [email protected]
Portugal
- Company: LabNet Biotechnica
- Address: Calle Maldonado, 56 - 28006 - Madrid – España
- Email: [email protected]
- Web: https://www.labnet.es/
- Company: tebu-bio
- Address: Gran Via de les Corts Catalanes, 583 - 5°
- 08011 Barcelona
- Tel: 93 306 34 10
- Fax: 93 306 34 99
- Email: [email protected]
- Web: https://www.tebu-bio.com/
- Company: VITRO S.A.
- Address: C/ Luis Fuentes Bejarano, 60 - Ed. Nudo Norte - 41020 Sevilla España
- Tel: +34 954 933 200 / +34 954 933 266
- Email: [email protected]
- Web: https://www.vitro.bio/
Spain
- Company: Biospectra d.o.o.
- Address: Industrijska cesta 5B.
- 5000 Nova Gorica
- SLOVENIJA
- Tel: +386 (0)5 333 13 28
- Fax: +386 (0)5 302 5335
- Email: [email protected]
Slovenia
- Company: Biospectra d.o.o.
- Address: Industrijska cesta 5B.
- 5000 Nova Gorica
- SLOVENIJA
- Tel: +386 (0)5 333 13 28
- Fax: +386 (0)5 302 5335
- Email: [email protected]
Serbia
- Company: tebu-bio
- Address: CAT Science Park
- Universitetsparken 7
- 4000 Roskilde - Denmark
- Tel: +45 46 74 02 54
- Email: [email protected]
- Web: https://www.tebu-bio.com/
Sweden
- Company: Axon Lab AG
- Address: Täfernstrasse 15, 5405 Baden, Switzerland
- Tel: +41 56 484 80 80
- Email: [email protected]
